ConductScience.org, home

Paper40078286

High-performance PBPK model for predicting CYP3A4 induction-mediated drug interactions: a refined and validated approach.

Yang CG and 5 others. Front Pharmacol, 2025. Cited by 3 papers, by iCite.

Cite this record

ConductScience Library. High-performance PBPK model for predicting CYP3A4 induction-mediated drug interactions: a refined and validated approach. Papers, record 40078286. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/40078286

Download JSON
Sources
11 sources
Release
papers-2026-11-12-0.1.0

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title
High-performance PBPK model for predicting CYP3A4 induction-mediated drug interactions: a refined and validated approach.
PubMed
Journal
Front Pharmacol
PubMed
Year
2025
PubMed
Publication types
Journal Article
PubMed
Citations, by iCite
3
iCite
Revised in PubMed
2025-03-14
PubMed

Authors6

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

OrderAuthorForenameKindORCID iD
1Yang CGCheng-Guang
2Chen TTao
3Si WTWen-Teng
4Wang AHAn-Hai
5Ren HCHong-Can
6Wang LLi

Source PubMed

Download CSV of authors

Topics0

NLM's MeSH indexing of the paper, its major topics first.

None in this release.

References52

The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.

OrderPMIDTitleJournalYearIn PapersSource
125851638Clinical assessment of drug-drug interactions of tasimelteon, a novel dual melatonin receptor agonist.J Clin Pharmacol2015https://conductscience.org/library/papers/25851638PubMed
226953185Evaluation of Rifampin's Transporter Inhibitory and CYP3A Inductive Effects on the Pharmacokinetics of Venetoclax, a BCL-2 Inhibitor: Results of a Single- and Multiple-Dose Study.J Clin Pharmacol2016https://conductscience.org/library/papers/26953185PubMed
326385839Physiologically-Based Pharmacokinetic Modeling of Macitentan: Prediction of Drug-Drug Interactions.Clin Pharmacokinet2016https://conductscience.org/library/papers/26385839PubMed
427506419New brominated flame retardants and their metabolites as activators of the pregnane X receptor.Toxicol Lett2016https://conductscience.org/library/papers/27506419PubMed
532387584Early discontinuation of tofacitinib in patients with rheumatoid arthritis co-treated with rifampin for latent tuberculosis.Joint Bone Spine2020https://conductscience.org/library/papers/32387584PubMed
627128004Impact on abiraterone pharmacokinetics and safety: Open-label drug-drug interaction studies with ketoconazole and rifampicin.Clin Pharmacol Drug Dev2015https://conductscience.org/library/papers/27128004PubMed
74087830Pharmacokinetics of oral and intravenous rifampicin during chronic administration.Klin Wochenschr1985https://conductscience.org/library/papers/4087830PubMed
826749408Effect of Rifampin on the Pharmacokinetics of Apixaban, an Oral Direct Inhibitor of Factor Xa.Am J Cardiovasc Drugs2016https://conductscience.org/library/papers/26749408PubMed
923852652Effects of cytochrome P450 inhibitors and inducers on the metabolism and pharmacokinetics of ospemifene.Biopharm Drug Dispos2013https://conductscience.org/library/papers/23852652PubMed
1024530864Physiologically based pharmacokinetic modeling of CYP3A4 induction by rifampicin in human: influence of time between substrate and inducer administration.Eur J Pharm Sci2014https://conductscience.org/library/papers/24530864PubMed
1121036951Critique of the two-fold measure of prediction success for ratios: application for the assessment of drug-drug interactions.Drug Metab Dispos2011https://conductscience.org/library/papers/21036951PubMed
1228912253Physiologically Based Pharmacokinetic Model Predictions of Panobinostat (LBH589) as a Victim and Perpetrator of Drug-Drug Interactions.Drug Metab Dispos2017https://conductscience.org/library/papers/28912253PubMed
1321602517The effect of CYP3A4 inhibition or induction on the pharmacokinetics and pharmacodynamics of orally administered ruxolitinib (INCB018424 phosphate) in healthy volunteers.J Clin Pharmacol2012https://conductscience.org/library/papers/21602517PubMed
1423995268Evaluation of various static and dynamic modeling methods to predict clinical CYP3A induction using in vitro CYP3A4 mRNA induction data.Clin Pharmacol Ther2014https://conductscience.org/library/papers/23995268PubMed
1531145690Drug-drug interaction (DDI) assessments of ruxolitinib, a dual substrate of CYP3A4 and CYP2C9, using a verified physiologically based pharmacokinetic (PBPK) model to support regulatory submissions.Drug Metab Pers Ther2019https://conductscience.org/library/papers/31145690PubMed
1634902744Development and application of a physiologically based pharmacokinetic model for entrectinib in rats and scale-up to humans: Route-dependent gut wall metabolism.Biomed Pharmacother2022https://conductscience.org/library/papers/34902744PubMed
1727367453Ibrutinib Dosing Strategies Based on Interaction Potential of CYP3A4 Perpetrators Using Physiologically Based Pharmacokinetic Modeling.Clin Pharmacol Ther2016https://conductscience.org/library/papers/27367453PubMed
1824086247Modeling of rifampicin-induced CYP3A4 activation dynamics for the prediction of clinical drug-drug interactions from in vitro data.PLoS One2013https://conductscience.org/library/papers/24086247PubMed
1924962564The impact of co-administration of ketoconazole and rifampicin on the pharmacokinetics of apremilast in healthy volunteers.Br J Clin Pharmacol2014https://conductscience.org/library/papers/24962564PubMed
2019843061Effects of rifampicin on the pharmacokinetics of roflumilast and roflumilast N-oxide in healthy subjects.Br J Clin Pharmacol2009https://conductscience.org/library/papers/19843061PubMed

See all 52 referencesDownload CSV of references

Cited by3

The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 3 citations.

PMIDTitleJournalYearIn PapersSource
42865646Microbiota-based PBPK model: new approach methodology for assessing the kinetics of drugs and chemicals.Front Pharmacol2026https://conductscience.org/library/papers/42865646PubMed
41788629Predicting drug-drug interactions between ayahuasca alkaloids and SSRIs using physiologically based pharmacokinetic modeling.Front Mol Biosci2026https://conductscience.org/library/papers/41788629PubMed
40642005Editorial: Application of PKPD modeling in drug discovery and development.Front Pharmacol2025https://conductscience.org/library/papers/40642005PubMed

Download CSV of cited by

Genes1

The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.

GeneNCBI Gene IDLinked byIn Genes
CYP3A41576PubTator's text mininghttps://conductscience.org/library/genes/1576

Source NCBI Gene

Download CSV of genes

Data dates

The date of each source this release read.

PubMed
2026-11-06
PubMed
iCite
2026-11-05
iCite
PMC's ID file
2026-11-05
PMC's ID file
NIH RePORTER's grant and paper links
2026-11-01
NIH RePORTER's grant and paper links
Trials
2026-11-12
Gene search
2026-11-11
Pipelines
2026-09-18

None in this release

  • Grants
  • Trials
  • Comments and corrections
  • Drugs
  • Data

Sources 11

  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • HGNCCC0
  • iCiteCC BY 4.0
  • NCBI GenePublic domain (US government)
  • NIH RePORTER's grant and paper linksPublic domain
  • Open TargetsCC0 1.0
  • PMC's ID filePublic domain (US government)
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • HGNCCC0: https://www.genenames.org/about/license/
  • iCiteCC BY 4.0
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/40078286

GET https://conductscience.org/api/papers/v1/40078286/references?page=2